Cullinan Therapeutics reported net income of -$53.97M for the quarter ended Jun 2026. This income statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 43.66M | 44.29M | 44.66M | 45.40M | 45.74M | 45.80M | 39.34M | 42.74M | 42.76M | 42.90M | 43.07M | 57.87M | 58.14M | 58.51M | 58.70M | 59.07M | 59.08M | 60.24M | 61.45M | 64.35M | ||||||
| Revenue & cost | ||||||||||||||||||||||||||
| Revenue | ||||||||||||||||||||||||||
| Operating items | ||||||||||||||||||||||||||
| Research & DevelopmentR&D | 12.68M | 20.88M | 24.54M | 26.41M | 19.68M | 21.32M | 52.10M | 27.39M | 33.82M | 34.85M | 30.65M | 36.26M | 35.51M | 40.49M | 41.46M | 61.03M | 41.97M | 42.95M | 42.12M | 44.44M | ||||||
| Selling, General & AdministrativeSG&A | 5.70M | 13.47M | 8.12M | 10.70M | 10.09M | 11.29M | 10.66M | 10.21M | 10.98M | 10.64M | 12.34M | 13.77M | 13.35M | 14.56M | 13.54M | 14.77M | 13.63M | 12.31M | 11.57M | 12.82M | ||||||
| Operating ExpensesOpex | 18.38M | 34.35M | 32.66M | 37.11M | 29.77M | 32.61M | 62.76M | 37.60M | 44.80M | 45.48M | 42.99M | 50.03M | 48.85M | 55.05M | 55.00M | 75.80M | 55.59M | 55.26M | 53.70M | 57.25M | ||||||
| Operating IncomeOp. Inc | -18.38M | -34.35M | -32.66M | 239.68M | -29.77M | -32.61M | -62.76M | -37.60M | -45.24M | -45.48M | -42.99M | -50.03M | -48.85M | -55.05M | -55.00M | -75.80M | -55.59M | -55.26M | -53.70M | -57.25M | ||||||
| EBIT | -18.38M | -34.35M | -32.66M | 239.68M | -29.77M | -32.61M | -62.76M | -37.60M | -45.24M | -45.48M | -42.99M | -50.03M | -48.85M | -55.05M | -55.00M | -75.80M | -55.59M | -55.26M | -53.70M | -57.25M | ||||||
| Non-operating items | ||||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.12M | 0.14M | 0.20M | 0.70M | 2.35M | 3.36M | 4.51M | 5.32M | 5.88M | 5.92M | 5.69M | 8.07M | 8.38M | 7.51M | 6.58M | 5.92M | 5.09M | 4.62M | 4.10M | 3.65M | ||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.00M | 0.00M | -0.24M | 0.30M | 0.11M | 0.07M | 0.18M | -0.12M | -0.04M | -0.07M | -0.09M | 0.01M | -0.09M | -0.18M | -0.11M | -0.07M | -0.06M | -0.10M | ||||||||
| Net income details | ||||||||||||||||||||||||||
| EBT | -18.26M | -34.21M | -32.46M | 240.13M | -27.41M | -28.95M | -58.14M | -32.21M | -39.18M | -39.69M | -37.30M | -41.96M | -40.47M | -47.54M | -48.42M | -69.87M | -50.50M | -50.64M | -49.60M | -53.61M | ||||||
| Tax ProvisionsTaxes | -19.60M | 66.07M | -2.52M | -1.88M | -14.12M | |||||||||||||||||||||
| Profit After TaxPAT | -18.26M | -34.21M | -12.89M | 174.06M | -24.89M | -26.78M | -58.14M | -32.21M | -39.18M | -25.56M | -37.34M | -42.03M | -40.56M | -47.65M | -48.50M | -70.06M | -50.61M | -50.71M | -49.66M | -53.97M | ||||||
| Income from Non-Controlling InterestsInc. Minority | -0.91M | -1.69M | 1.20M | -0.83M | -0.09M | -0.31M | -0.18M | -1.76M | -0.19M | |||||||||||||||||
| Income from Continuing OperationsIncome (Continuing) | -18.26M | -34.21M | -12.86M | 174.06M | -24.89M | -27.07M | -58.14M | -32.21M | -39.18M | -25.56M | -37.30M | -41.96M | -40.47M | -47.54M | -48.42M | -69.87M | -50.50M | -50.64M | -49.60M | -53.61M | ||||||
| Consolidated Net IncomeConsol Net Inc. | -18.26M | -34.21M | -12.86M | 174.06M | -24.89M | -27.07M | -58.14M | -32.21M | -39.18M | -25.56M | -37.30M | -41.96M | -40.47M | -47.54M | -48.42M | -69.87M | -50.50M | -50.64M | -49.60M | -53.61M | ||||||
| Income towards Parent CompanyParent Net Inc | -18.26M | -34.21M | -12.86M | 174.06M | -24.89M | -27.07M | -58.14M | -32.21M | -39.18M | -25.56M | -37.30M | -41.96M | -40.47M | -47.54M | -48.42M | -69.87M | -50.50M | -50.64M | -49.60M | -53.61M | ||||||
| Net Income towards Common StockholdersNet Income | -18.26M | -34.21M | -12.86M | 174.06M | -24.89M | -27.07M | -58.14M | -32.21M | -39.18M | -25.56M | -37.30M | -41.96M | -40.47M | -47.54M | -48.42M | -69.87M | -50.50M | -50.64M | -49.60M | -53.61M | ||||||
| Additional items | ||||||||||||||||||||||||||
| EPS (Basic) | -0.42 | -0.79 | -0.29 | 3.88 | -0.55 | -0.60 | -1.43 | -0.81 | -0.92 | -0.61 | -0.85 | -0.75 | -0.69 | -0.87 | -0.82 | -1.17 | -0.85 | -0.86 | -0.82 | -0.87 | ||||||
| EPS (Diluted) | -0.42 | -0.79 | -0.29 | 3.75 | -0.55 | -0.58 | -1.43 | -0.81 | -0.92 | -0.61 | -0.85 | -0.75 | -0.69 | -0.88 | -0.82 | -1.17 | -0.85 | -0.85 | -0.81 | -0.87 | ||||||
| Shares Outstanding | 43.44M | 43.08M | 44.43M | 44.87M | 45.61M | 45.16M | 40.68M | 39.95M | 42.73M | 42.16M | 43.66M | 55.70M | 58.98M | 54.42M | 58.91M | 59.66M | 59.08M | 59.05M | 60.46M | 61.97M | ||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 43.44M | 43.08M | 44.43M | 46.38M | 45.61M | 46.64M | 40.68M | 39.95M | 42.73M | 42.16M | 43.66M | 55.70M | 58.98M | 53.77M | 58.91M | 59.66M | 59.72M | 59.70M | 61.02M | 61.97M | ||||||
| EBITDA | -18.38M | -34.35M | -32.66M | 239.68M | -29.77M | -32.61M | -62.76M | -37.60M | -45.24M | -45.48M | -42.99M | -50.03M | -48.85M | -55.05M | -55.00M | -75.80M | -55.59M | -55.26M | -53.70M | -57.25M | ||||||
| Tax Rate | 60.38 | 27.51 | 9.20 | 6.49 | 35.59 |